Immunocan Secures RMB250 Million Series A Funding to Accelerate Gene-Edited Animal Platforms and AI-Driven Antibody Discovery

Shanghai-based Immunocan, a burgeoning biopharmaceutical company at the forefront of antibody discovery and gene-editing technologies, has successfully closed a RMB250 million (approximately $34.5 million USD) Series A funding round. This…